Sugi Predict

Sugi Predict / Targets / AXL

AXL

Tyrosine-protein kinase receptor UFO · P30530 · AXL on Sugi Atlas →

184,668 patent compounds predicted against AXL, 120,306 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL104767 SCHEMBL104767 0.62 14/20
SCHEMBL140985 SCHEMBL140985 0.54 14/20
SCHEMBL143451 SCHEMBL143451 0.51 11/20
SCHEMBL105748 SCHEMBL105748 0.49 11/20
SCHEMBL138269 SCHEMBL138269 0.50 10/20
SCHEMBL142781 SCHEMBL142781 0.49 10/20
SCHEMBL142782 SCHEMBL142782 0.49 10/20
SCHEMBL106402 SCHEMBL106402 0.53 9/20
SCHEMBL140837 SCHEMBL140837 0.50 9/20
SCHEMBL141531 SCHEMBL141531 0.48 9/20
SCHEMBL74518 SCHEMBL74518 0.44 9/20
SCHEMBL138396 SCHEMBL138396 0.51 8/20
SCHEMBL138412 SCHEMBL138412 0.49 8/20
SCHEMBL143639 SCHEMBL143639 0.49 8/20
SCHEMBL143640 SCHEMBL143640 0.49 8/20
SCHEMBL143778 SCHEMBL143778 0.49 8/20
SCHEMBL143823 SCHEMBL143823 0.49 8/20
SCHEMBL105727 SCHEMBL105727 0.49 8/20
SCHEMBL139086 SCHEMBL139086 0.46 8/20
SCHEMBL139087 SCHEMBL139087 0.46 8/20

Clinical trials — most relevant to AXL by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study PHASE2/PHASE3COMPLETED
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer PHASE3COMPLETED
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC) PHASE3COMPLETED
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA) PHASE2RECRUITING
A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) PHASE2RECRUITING
Cabozantinib for Progressive HCC Post-first-line Immuno-oncologic Combination Therapy PHASE2NOT_YET_RECRUITING
Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy PHASE2WITHDRAWN
Cabozantinib for Advanced Urothelial Cancer PHASE2COMPLETED
Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma PHASE2COMPLETED
Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes PHASE2COMPLETED
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System PHASE2WITHDRAWN
Phase II Dasatinib Study in Advanced Breast Cancer PHASE2COMPLETED
Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases PHASE2COMPLETED
Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) PHASE1/PHASE2COMPLETED
Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer PHASE2UNKNOWN
Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung PHASE2COMPLETED
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC PHASE2ACTIVE_NOT_RECRUITING
Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer PHASE2COMPLETED
Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML PHASE2COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer PHASE2COMPLETED
Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies PHASE1COMPLETED
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas PHASE1COMPLETED
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer PHASE1COMPLETED
Rapid Sequencing of Approved Therapies in Patients with Metastatic or Unresectable Clear Cell Renal Cell Carcinoma EARLY_PHASE1RECRUITING
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC) nanRECRUITING
Blood and Tumor Tissue Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
MERTK Signalling in Monocytes/Macrophages in Patients With Liver Disease nanCOMPLETED
Role of the Gut Microbiome in Anti-tumor Therapy Induced Diarrhea nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a AXL binder may also engage these)

ProteinNameSimilarity
Q00993 — 0.999 Q00993 →
P55146 — 0.987 P55146 →
TYRO3 Tyrosine-protein kinase receptor TYRO3 0.986 landscape →
P55144 — 0.986 P55144 →
P35739 — 0.984 P35739 →
Q3UFB7 — 0.983 Q3UFB7 →
Q98949 — 0.982 Q98949 →
LTK Leukocyte tyrosine kinase receptor 0.981 landscape →
P08923 — 0.981 P08923 →
FGFR4 Fibroblast growth factor receptor 4 0.979 landscape →
A0JM20 — 0.977 A0JM20 →
Q05BQ1 — 0.976 Q05BQ1 →
NTRK1 High affinity nerve growth factor receptor 0.975 landscape →
P57097 — 0.975 P57097 →
MAP4K2 Mitogen-activated protein kinase kinase kinase kinase 2 0.975 landscape →
Q9P2J2 — 0.974 Q9P2J2 →
Q8R007 — 0.974 Q8R007 →
Q03142 — 0.974 Q03142 →
Q498D6 — 0.974 Q498D6 →
NECTIN4 Nectin-4 0.974 landscape →
MERTK Tyrosine-protein kinase Mer 0.973 landscape →
Q60805 — 0.973 Q60805 →
Q8QFP9 — 0.973 Q8QFP9 →
Q9MZ08 — 0.973 Q9MZ08 →
Q8K045 — 0.973 Q8K045 →
P50895 — 0.973 P50895 →
P23049 — 0.972 P23049 →
PKN3 Serine/threonine-protein kinase N3 0.972 landscape →
Q9YI66 — 0.971 Q9YI66 →
P0C5H6 — 0.971 P0C5H6 →